LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSalud

3.89 -13.75

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.82

Máximo

3.91

Métricas clave
By Trading Economics
Ingresos	11M -35M
Ventas	13M 17M
Margen de beneficio	-203.272
Empleados	596
EBITDA	769K -39M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+79.03% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	309M 1.6B
Apertura anterior	17.64
Cierre anterior	3.89

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

323 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.99 / 2.635 Soporte y Resistencia

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 nov 2025, 21:06 UTC

Principales Movimientos del Mercado

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Ganancias

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Ganancias

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Charlas de Mercado

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Ganancias

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Charlas de Mercado

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Charlas de Mercado

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Ganancias

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Ganancias

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Charlas de Mercado

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

7 nov 2025, 17:17 UTC

Adquisiciones, fusiones, absorciones

Satair Expects to Complete Purchase in Early 2026

7 nov 2025, 17:17 UTC

Adquisiciones, fusiones, absorciones

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 nov 2025, 17:15 UTC

Adquisiciones, fusiones, absorciones

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7 nov 2025, 17:09 UTC

Charlas de Mercado

PENN Is Falling Further Behind Competitors -- Market Talk

7 nov 2025, 16:49 UTC

Charlas de Mercado

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7 nov 2025, 16:24 UTC

Charlas de Mercado

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7 nov 2025, 16:17 UTC

Charlas de Mercado

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

79.03% repunte

Estimación a 12 meses

Media 7 USD 79.03%

Máximo 10 USD

Mínimo 4 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

323 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.